224 related articles for article (PubMed ID: 31659868)
1. Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo
Raychaudhuri S; Abria C; Harmany ZT; Smith CM; Kundu-Raychaudhuri S; Raychaudhuri SP; Chaudhari AJ
Int J Rheum Dis; 2019 Dec; 22(12):2165-2169. PubMed ID: 31659868
[TBL] [Abstract][Full Text] [Related]
2. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
Lomonte ABV; Radominski SC; Marcolino FMD; Brenol CV; Zerbini CAF; García EG; Akylbekova EL; Rojo R; de Leon DP
Medicine (Baltimore); 2018 Aug; 97(31):e11609. PubMed ID: 30075534
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Krishnaswami S; Boy M; Chow V; Chan G
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
[TBL] [Abstract][Full Text] [Related]
5. Single- and multiple-dose pharmacokinetics of tofacitinib in healthy Chinese volunteers.
Krishnaswami S; Wang T; Yuan Y; Alvey CW; Checchio T; Peterson M; Shi H; Riese R
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):395-9. PubMed ID: 27137149
[TBL] [Abstract][Full Text] [Related]
6. Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis.
Wei X; Wu J; Zhao G; Galdamez J; Lele SM; Wang X; Liu Y; Soni DM; Purdue PE; Mikuls TR; Goldring SR; Wang D
Mol Pharm; 2018 Aug; 15(8):3456-3467. PubMed ID: 29966420
[TBL] [Abstract][Full Text] [Related]
7. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Li Z; An Y; Su H; Li X; Xu J; Zheng Y; Li G; Kwok K; Wang L; Wu Q
Int J Rheum Dis; 2018 Feb; 21(2):402-414. PubMed ID: 29314645
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib versus methotrexate in rheumatoid arthritis.
Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
[TBL] [Abstract][Full Text] [Related]
11. [(18)]F FDG PET/CT imaging to monitor the therapeutic effect of liposome-encapsulated prednisolone in experimental rheumatoid arthritis.
van der Geest T; Metselaar JM; Gerrits D; van Lent PL; Storm G; Laverman P; Boerman OC
J Control Release; 2015 Jul; 209():20-6. PubMed ID: 25902038
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2.
Klamerus KJ; Alvey C; Li L; Feng B; Wang R; Kaplan I; Shi H; Dowty ME; Krishnaswami S
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):499-507. PubMed ID: 27129125
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Fleischmann R; Mease PJ; Schwartzman S; Hwang LJ; Soma K; Connell CA; Takiya L; Bananis E
Clin Rheumatol; 2017 Jan; 36(1):15-24. PubMed ID: 27734232
[TBL] [Abstract][Full Text] [Related]
14. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
Conaghan PG; Østergaard M; Bowes MA; Wu C; Fuerst T; van der Heijde D; Irazoque-Palazuelos F; Soto-Raices O; Hrycaj P; Xie Z; Zhang R; Wyman BT; Bradley JD; Soma K; Wilkinson B
Ann Rheum Dis; 2016 Jun; 75(6):1024-33. PubMed ID: 27002108
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
Tanaka Y; Maeshima K; Yamaoka K
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies.
Fleischmann R; Kremer J; Tanaka Y; Gruben D; Kanik K; Koncz T; Krishnaswami S; Wallenstein G; Wilkinson B; Zwillich SH; Keystone E
Int J Rheum Dis; 2016 Dec; 19(12):1216-1225. PubMed ID: 27451980
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a Level A in-vitro in-vivo correlation for tofacitinib modified-release tablets using extrudable core system osmotic delivery technology.
Kushner J; Lamba M; Stock T; Wang R; Nemeth MA; Alvey C; Chen R; DeMatteo V; Blanchard A
Eur J Pharm Sci; 2020 Apr; 147():105200. PubMed ID: 31863865
[TBL] [Abstract][Full Text] [Related]
19. A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.
Fleischmann R
Expert Opin Pharmacother; 2017 Oct; 18(14):1525-1533. PubMed ID: 28829236
[TBL] [Abstract][Full Text] [Related]
20. Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study.
Balagué C; Pont M; Prats N; Godessart N
Br J Pharmacol; 2012 Jun; 166(4):1320-32. PubMed ID: 22229697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
